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Objective: Neurotensin and xenin are two closely related anorexigenic neuropeptides
synthesized in the small intestine that exert diverse peripheral and central functions.
Both act via the neurotensin-1-receptor. In animal models of obesity reduced central
concentrations of these peptides have been found. Dysregulations of the acute and
chronic stress response are associated with development and maintenance of obesity.
Until now, associations of both peptides with stress, anxiety, depressiveness, and eating
disorder symptoms have not been investigated. The aim of the present study was to
examine associations of neurotensin and xenin with these psychological characteristics
under conditions of obesity.
Materials and Methods: From 2010 to 2016 we consecutively enrolled 160 inpatients
(63 men and 97 women), admitted due to obesity and its mental and somatic
comorbidities. Blood withdrawal und psychometric tests (PSQ-20, GAD-7, PHQ-9, and
EDI-2) occurred within one week after admission. We measured levels of neurotensin
and xenin in plasma by ELISA.
Results: Mean body mass index was 47.2 ± 9.5 kg/m2. Concentrations of neurotensin
and xenin positively correlated with each other (women: r = 0.788, p < 0.001; men:
r = 0.731, p < 0.001) and did not significantly differ between sexes (p > 0.05). Women
generally displayed higher psychometric values than men (PSQ-20: 58.2 ± 21.7 vs.
47.0 ± 20.8, p = 0.002; GAD-7: 9.7 ± 5.8 vs. 7.1 ± 5.3, p = 0.004; PHQ-9: 11.6 ± 6.6
vs. 8.8 ± 5.9, p = 0.008; EDI-2: 50.5 ± 12.8 vs. 39.7 ± 11.9, p < 0.001). Only women
showed positive correlations of both neuropeptides with stress (neurotensin: r = 0.231,
p = 0.023; xenin: r = 0.254, p = 0.013), anxiety (neurotensin: r = 0.265, p = 0.009;
xenin: r = 0.257, p = 0.012), depressiveness (neurotensin: r = 0.281, p = 0.006; xenin:
r = 0.241, p = 0.019) and eating disorder symptoms (neurotensin: r = 0.276, p = 0.007;
xenin: r = 0.26, p = 0.011), whereas, men did not (p > 0.05).
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Conclusion: Neurotensin and xenin plasma levels of female obese patients are
positively correlated with perceived stress, anxiety, depressiveness, and eating disorder
symptoms. These associations could be influenced by higher prevalence of mental
disorders in women and by sex hormones. In men, no correlations were observed,
which points toward a sex-dependent regulation.
Keywords: gut-brain axis, obesity, psychiatric, psychosomatic, sex difference
HIGHLIGHTS
- Neurotensin and xenin are long-known neuropeptides with
anorexigenic effects.
- Neurotensin and xenin seem to be associated with
psychopathology under conditions of obesity.
- Sex-specific regulation of neurotensin and xenin was found for
perceived stress and anxiety.
- Only in obese women neurotensin and xenin showed
positive correlations with depressiveness and eating
disorder symptoms.
- Alterations of circulating levels of neurotensin and xenin may
be involved in the emergence and maintenance of obesity.
INTRODUCTION
With a worldwide prevalence of 13.1%, which has increased
threefold since 1975, obesity (body mass index, BMI≥ 30 kg/m2)
is a widespread and serious disease, mostly because of its
physical and mental comorbidities (World Health Organization,
2017, 2020). In Europe, 23.3% of the adult population is
obese (World Health Organization, 2017). The prevalence
of 38.2% in the United States of America is critically
high among adults (Organisation for Economic Co-operation
and Development, 2017). Comorbidities of obesity include
dyslipidemia and insulin resistance together with manifest
diabetes mellitus type 2 and arterial hypertension (Grundy,
2002; Garg et al., 2014). In addition, mental comorbidities
are associated with obesity (Petry et al., 2008; Preiss et al.,
2013; Herpertz, 2015). Depressive, anxiety, somatoform, and
binge eating disorders (BED) are the most frequent ones (Petry
et al., 2008; Preiss et al., 2013; Herpertz, 2015). Moreover,
psychosocial risk factors are involved in the etiology of
obesity and obesity itself is a risk factor of major depression
(Herpertz, 2015).
Furthermore, increased levels of perceived acute and chronic
stress along with dysregulations of the endocrine stress
response likely contribute to the genesis and maintenance of
obesity (Morris et al., 2015). Chronic stress is biologically
reflected by enduring stimulation of the hypothalamic-pituitary-
adrenal (HPA) axis leading to elevated levels of circulating
glucocorticoids (Strack et al., 1995; Morris et al., 2015).
Subsequent catabolic effects and the impact on energy balance
in terms of orexigenic signaling (e.g., via neuropeptide Y,
NPY) further contribute to the maintenance of obesity and its
comorbidities (Strack et al., 1995; Chrousos, 2009). Moreover,
a pro-inflammatory state due to large amounts of endocrinely
active visceral fat tissue, which is another stimulus of the HPA
axis, and increased stress levels are in close interaction (Nezi
et al., 2000; Tilg and Moschen, 2006). An important connection
of this psychobiological relationship is the bidirectional gut-
brain axis (Lee and Abizaid, 2014). In this crosstalk, intestinally
and centrally secreted peptides are crucial (Holzer and Farzi,
2014; Lach et al., 2018). Long-term regulation of energy
balance and body weight is redundantly regulated by several
important hormones, e.g., insulin, leptin, and ghrelin (Pape,
2014). Therefore, dysregulation of peptides of the gut-brain
axis are in the focus of obesity research (Beck, 2000; Boughton
and Murphy, 2013). Nevertheless, several potentially relevant
peptides have not yet been investigated in this context.
Peptides of the highly conserved neurotensin/xenopsin/xenin
family exert diverse peripheral and central functions
along the gut-brain axis (Feurle, 1998). A central
anorexigenic effect by neurotensin and xenin was
shown in rats, whereas, this effect has not been shown
yet for the amphibian peptide xenopsin (Araki et al.,
1975; Luttinger et al., 1982; Alexiou et al., 1998;
McConn et al., 2015).
Neurotensin, a tridecapeptide, was detected in bovine
hypothalamus (Carraway and Leeman, 1973). It is derived from
the same precursor protein as neuromedin N (NMN), secreted
in the central nervous system (CNS) and peripherally by N-cells
of the intestinal mucosa due to postprandially increased free
fatty acids (Kislauskis et al., 1988; Malendowicz, 1998; Schroeder
and Leinninger, 2018). Important brain areas of neurotensin
secretion are amygdala, hippocampus, ventral tegmental area
(VTA), arcuate, and paraventricular nuclei (St-Gelais et al.,
2006). Besides the anti-hypertensive effect of the peptide, many
other effects were discovered (Blackburn, 1978) encompassing a
stimulation of gut motility and pancreatic secretion of glucagon
and insulin, a reduction of gastric acid secretion and a role
as growth factor (Blackburn et al., 1980; Yawata et al., 1984;
Carraway and Plona, 2006; Kalafatakis and Triantafyllou, 2011).
Central effects of neurotensin are hypothermia, food intake
suppression, and opioid-independent analgesia as well as an
endogenous antipsychotic activity because of interactions with
the dopaminergic system (Martin et al., 1980; Luttinger et al.,
1982; Furuta et al., 1984; Fuxe et al., 1992). Furthermore,
neurotensin displays regulatory functions in pituitary secretion
of luteinizing hormone (LH) and follicle-stimulating hormone
(FSH) (Herbison and Theodosis, 1991, 1992). Four different
receptors are responsible for the physiological effects of
neurotensin, especially the high-affinity neurotensin-receptor-1
(NTS1) and low-affinity neurotensin-receptor-2 (NTS2), which
are G-protein-coupled-receptors (GPCRs) (Tanaka et al., 1990;
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Chalon et al., 1996; Mazella et al., 1998; Jacobsen et al.,
2001).
Xenin, was discovered in 1992 but is still relatively little
studied (Feurle et al., 1992). The 25 amino acid peptide hormone
is released by enteroendocrine K-cells of the duodenum (Anlauf
et al., 2000). The same cells synthesize glucose-dependent
insulinotropic peptide (GIP) whose functions are closely related
to the peripheral effects of xenin (Anlauf et al., 2000; Cho
and Kieffer, 2010). Despite identical cells of origin in the
duodenum, no sequence homology exists between the 42-amino
acid polypeptide GIP and xenin (Feurle, 1998; Yip and Wolfe,
2000). GIP binds to the glucose-inhibitory peptide receptor,
whereas, xenin primarily acts via the NTS1 (Clemens et al., 1997;
Baggio and Drucker, 2007; Kim et al., 2016).
As observed for neurotensin, peripheral xenin is primarily
released postprandially inducing a delayed gastric emptying
rate, contraction of gall bladder, lipolysis of white adipose
tissue, and stimulation of exocrine and endocrine pancreatic
functions associated with an antidiabetic effect (Feurle et al., 1992;
Kamiyama et al., 2007; Kim and Mizuno, 2010a; Wice et al.,
2012; Bhavya et al., 2018). In the CNS, xenin suppresses appetite
through effects on several food intake-regulatory centers in the
hypothalamus and brainstem independent of melanocortin and
leptin signaling pathways (Nandar et al., 2008; Leckstrom et al.,
2009; Kim and Mizuno, 2010a). Xenin and neurotensin show
20% sequence homology (five amino acids in identical position),
especially near the C-terminus (Yip and Wolfe, 2000).
Due to their physiological effects, both neurotensin and xenin
have been examined in the context of obesity and in relation
to somatic sequelae of the disease (Craig et al., 2018; Schroeder
and Leinninger, 2018). Antidiabetic properties of xenin and
dysregulations of neurotensin and pro-neurotensin in obesity
and high-fat diet are current areas of interest (Weiss et al., 2001;
Wice et al., 2010; Gault et al., 2015; Li et al., 2016; Hasib et al.,
2017). Moreover, anorexigenic effects of both peptides have been
examined, because in animal models of obesity, decreased central
concentrations of neurotensin have been detected together
with reduced food intake after intracerebroventricular (icv)
administration of xenin and neurotensin in rodents (Beck et al.,
1990; Williams et al., 1991a; Cooke et al., 2009). Until now,
mental conditions of obese patients and xenin levels have not
been investigated.
The aim of the present study was to investigate potential
associations between plasma levels of neurotensin and xenin
and perceived stress, anxiety, depressiveness, and eating disorder
symptoms in obese inpatients. Women and men were examined
separately since expression of neurotensin and were shown




Investigations were conducted according to the Declaration
of Helsinki. All participants gave written informed consent
and the study was approved by the institutional ethics
committee of the Charité – Universitätsmedizin Berlin (protocol
number: EA1/130/16).
In the period between September 2010 and December
2016 we consecutively recruited 160 obese inpatients (97
women and 63 men). All participants were hospitalized
in the Department of Psychosomatic Medicine Charité –
Universitätsmedizin Berlin, where they received therapy due
to obesity and its mental and somatic comorbidities. Inclusion
criteria encompassed a BMI ≥ 30 kg/m2 and a minimum age
of 18 years. Current pregnancy or lactation period, dialysis,
hypercortisolism, malignoma, psychotic disorders as well as
treatment with immunomodulatory drugs (e.g., methotrexate,
azathioprine, and oral corticosteroids) were exclusion criteria.
Furthermore, patients with somatic or somatoform disorders of
the gastrointestinal tract or after surgery of the gastrointestinal
tract including bariatric operations, except for appendectomy,
and uncomplicated cholecystectomy, were excluded.
Procedure
Study enrolment including clarification of potential exclusion
criteria and blood withdrawal was conducted within four days
after admission. Venous blood sample from a forearm vein of
overnight fasted patients was taken every Friday between 7.00 am
and 8.00 am. It was permitted to drink a small amount of water,
but patients were not allowed to drink coffee or exercise before
blood collection. Patients were also advised not to smoke prior
to blood withdrawal. At the same morning we assessed actual
medication, body height and fasting weight of participants in
light underwear to calculate the BMI.
Psychometric Measurements
Associated psychometric data collection occurred no more than
two days before or five days after blood withdrawal. The following
self-reported questionnaires were completed by the participants.
The Perceived Stress Questionnaire (PSQ) was used to
evaluate the severity of subjective stress perception (Levenstein
et al., 1993) with the shortened 20-item version (PSQ-20) by
Fliege et al. (2005). The questionnaire encompasses the subscales
“worries,” “tension,” “joy” with relation to the stress response
and “demands” regarding the perception of external stressors
(Levenstein et al., 1993). Scores ranged from zero to 100.
Crohnbach’s alpha for the current sample was 0.892, 0.904, 0.824,
and 0.838 for the four subscales, respectively, and 0.872 for
the total score.
To evaluate the levels of anxiety and depression, we used two
subscales of the Patient Health Questionnaire (PHQ) (Spitzer
et al., 1999). For the assessment of anxiety, we used the German
version (Löwe et al., 2008) of the Generalized Anxiety Disorder-7
(GAD-7) scale with seven items (4-point Likert scale with a range
from zero up to three) as an established and widely used tool
(Spitzer et al., 2006). Crohnbach’s alpha for the current sample
was 0.903. The PHQ-9 with total scores from zero to 27 was
designed to measure the severity of depressive symptoms and
consists of nine items (Spitzer et al., 1999). We employed the
German version of the subscale (Löwe et al., 2002). Crohnbach’s
alpha for the current sample was 0.894.
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The severity of eating disorder symptoms was measured
by the Eating Disorder Inventory (EDI), which consists of
64 items (Garner et al., 1983). EDI comprises eight subscales
covering different aspects of eating disorders: “drive for
thinness,” “bulimia,” “body dissatisfaction,” “ineffectiveness,”
“perfectionism,” “interpersonal distrust,” “interoceptive
awareness,” and “maturity fears.” In detail, the German version
of the EDI-2, a revised version of the EDI with three additional
subscales (which were not applied in the current study) was used.
Scores range from zero to 100 (Garner, 1991; Thiel et al., 1997).
Crohnbach’s alpha for the current sample was 0.795, 0.896, 0.856,
0.901, 0.748, 0.784, 0.872, and 0.690 for the eight subscales,
respectively, and 0.809 for the total score.
Laboratory Analysis
Venous blood samples were collected in chilled standard
laboratory EDTA tubes containing aprotinin (1.2 Trypsin
Inhibitory Unit per 1 ml blood; ICN Pharmaceuticals,
Costa Mesa, CA, United States) as peptidase inhibitor
and stored on ice immediately after withdrawal. EDTA
tubes were then centrifuged at 4◦C for 10 min at 3000 g.
Blood plasma of each sample was separated and stored
at −80◦C. Neurotensin and xenin were measured by the
use of enzyme-linked immunosorbent assays (ELISA,
neurotensin: catalog # EK-048-03, xenin: catalog # EK-
046-74, Phoenix Pharmaceuticals Inc., Burlingame, CA,
United States, 0% cross reactivity between both analytes
according to manufacturer’s information). For neurotensin,
the intra-assay variability was 5.8% and for xenin 7.3%.
Every measurement was conducted twice, whereof we
calculated the mean value.
Statistical Analysis
Kolmogorov-Smirnov test was used to determine the distribution
of the data. Because all data were normally distributed, we
employed t-tests and chi-square tests analyzing differences
between two groups. Effect sizes were estimated by Cohen’s d
(t-test), Phi-coefficient ϕ (chi-square test) or Cramér’s V (chi-
square test). Correlations were assessed using Pearson’s analysis.
The correlations and differences between groups were considered
significant when p < 0.05. Due to the explorative character of
the study no p adjustment has been performed. Multivariable
linear regression was used to investigate the effect of age, gender,
various comorbidities and medication. Data are expressed as
mean ± standard derivation (SD) and statistical analyses were
executed using SigmaStat 3.1 (Systat Software, San Jose, CA,
United States) and IBM SPSS Statistics Version 26.0.0.0 (IBM
corp, Armonk, NY, United States).
RESULTS
Characterization of the Study Population
Anthropometric, endocrine and psychometric characteristics of
the study population (n = 160) and a comparison between
women and men are presented in Table 1. Mean BMI was
47.2 ± 9.5 kg/m2 (range: 31.8–75.1 kg/m2) and mean age
45.5 ± 13.7 years (range: 19–73 years). PSQ-20 data was missing
TABLE 1 | Anthropometric, psychometric, and endocrine characteristics of study populations.
Parameter Men (n = 63) Women (n = 97) p d
Age (years) 47.5 ± 13.6 (19–73) 44.2 ± 13.5 (20–73) 0.131 0.246
BMI (kg/m2) 45.5 ± 8.2 (32–67) 48.4 ± 10.0 (33–75) 0.059 0.307
PSQ-20 total score 47.0 ± 20.8 (3–95) 58.2 ± 21.7 (2–98) 0.002 0.521
- Worries 42.6 ± 24.9 (0–100) 59.1 ± 27.2 (0–100) <0.001 0.624
- Tension 50.2 ± 26.7 (0–100) 61.6 ± 27.1 (0–100) 0.011 0.420
- Joy 42.5 ± 22.9 (0–100) 37.7 ± 24.0 (0–100) 0.214 0.203
- Demands 37.5 ± 25.2 (0–100) 49.6 ± 23.9 (0–100) 0.003 0.493
GAD-7 total score 7.1 ± 5.3 (0–20) 9.7 ± 5.8 (0–21) 0.004 0.469
PHQ-9 total score 8.8 ± 5.9 (0–25) 11.6 ± 6.6 (1–26) 0.008 0.436
EDI-2 total score 39.7 ± 11.9 (19–72) 50.5 ± 12.8 (27–84) <0.001 0.866
- Drive for thinness 50.1 ± 21.6 (9–97) 61.3 ± 20.0 (17–97) 0.001 0.541
- Bulimia 22.2 ± 19.3 (0–74) 29.6 ± 24.4 (0–97) 0.046 0.327
- Body dissatisfaction 71.5 ± 21.7 (33–100) 89.4 ± 13.7 (46–100) <0.001 1.030
- Ineffectiveness 31.1 ± 18.2 (0–78) 46.2 ± 21.0 (6–90) <0.001 0.751
- Perfectionism 38.6 ± 19.0 (7–87) 43.2 ± 20.4 (7–93) 0.155 0.232
- Interpersonal distrust 40.3 ± 17.8 (0–80) 47.4 ± 17.4 (9–89) 0.013 0.405
- Interoceptive awareness 26.4 ± 18.2 (0–82) 39.8 ± 18.3 (6–90) <0.001 0.726
- Maturity fears 37.5 ± 17.0 (10–86) 42.7 ± 16.8 (8–100) 0.064 0.302
Neurotensin (ng/ml) 0.8 ± 0.3 (0.1–1.8) 0.8 ± 0.5 (0.2–3.6) 0.835 0.034
Xenin (ng/ml) 0.9 ± 0.4 (0.3–2.4) 1.0 ± 0.5 (0.3–2.9) 0.131 0.247
Data are expressed as mean ± SD, the range is indicated in parentheses. Differences between the two groups were assessed using t-test. Significant p values are
indicated in bold. Cohen‘s d is indicated as marker for the effect size. BMI, body mass index; EDI-2, Eating Disorder Inventory-2; GAD-7, Generalized Anxiety Disorder-7;
PHQ-9, Patient Health Questionnaire-9; PSQ-20, Perceived Stress Questionnaire-20.
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TABLE 2 | Demographic and socioeconomic characteristics, comorbidities and medication.
Parameter Whole population (n = 160) Women (n = 97) Men (n = 63) p ϕ / V
Socioeconomic characteristics
Living in a partnership 64 (40%) 41 (42.27%) 23 (36.51%) 0.467 −0.057
Level of education 0.246 0.184
University entrance diploma 35 (21.88%) 16 (16.49%) 19 (30.16%)
Vocational diploma 8 (5%) 5 (5.15%) 3 (4.76%)
Secondary education certificate 65 (40.63%) 44 (45.36%) 21 (33.33%)
Basic school qualification 38 (23.75%) 22 (22.68%) 16 (25.4%)
No school-leaving qualification 14 (8.75%) 10 (10.31%) 4 (6.35%)
Currently employed 45 (28.13%) 26 (26.8%) 19 (30.16%) 0.645 0.036
Unemployment during past 5 years 71 (44.38%) 41 (42.27%) 30 (47.62%) 0.506 0.053
Comorbidities
Bulimia Nervosa 2 (1.25%) 2 (2.06%) 0 (0%) 0.251 0.091
Binge-eating disorder 32 (20%) 27 (27.84%) 5 (7.94%) 0.002 0.243
Sleep-associated breathing disorder (women: n = 79; men: n = 56) 64 (47.41%) 28 (35.44%) 36 (64.29%) <0.001 −0.258
Type 2 diabetes mellitus 52 (32.5%) 29 (29.9%) 23 (36.51%) 0.383 −0.069
Arterial hypertension 102 (63.75%) 52 (53.61%) 50 (79.37%) <0.001 −0.262
Hypercholesterinemia 87 (54.38%) 45 (46.39%) 42 (66.6%) 0.012 −0.199
Hypertriglyceridemia 43 (26.88%) 20 (20.62%) 23 (36.51%) 0.027 −0.175
Hyperuricemia (women: n = 89; men: n = 61) 69 (46%) 38 (42.7%) 31 (50.82%) 0.327 −0.080
Fatty liver disease (women: n = 75; men: n = 43) 79 (66.95%) 46 (61.33%) 33 (76.74%) 0.087 −0.158
Medication
Insulin 18 (11.25%) 7 (7.22%) 11 (17.46%) 0.045 −0.158
DPP-4 antagonists/GLP-1 analogs 10 (6.25%) 5 (5.15%) 5 (7.94%) 0.478 −0.056
Antidiabetics (other) 32 (20%) 18 (18.56%) 14 (22.22%) 0.571 −0.045
Proton-pump inhibitor 49 (30.63%) 27 (27.84%) 22 (34.92%) 0.342 −0.075
Non-steroidal anti-inflammatory drugs 50 (31.25%) 29 (29.90%) 21 (33.34%) 0.647 −0.036
Psychopharmacological treatment 59 (36.88%) 39 (40.21%) 20 (31.75%) 0.278 0.086
Neuroleptics 19 (11.88%) 12 (12.37%) 7 (11.11%) 0.810 0.019
SSRI/SNRI 39 (24.38%) 28 (28.87%) 11 (17.46%) 0.101 0.130
Tricyclic antidepressants 10 (6.25%) 7 (7.22%) 3 (4.76%) 0.531 0.050
Other antidepressants 9 (5.63%) 6 (6.19%) 3 (4.76%) 0.703 0.030
Tranquilizers, sedatives, hypnotics 2 (1.25%) 1 (1.03%) 1 (1.59%) 0.757 −0.024
Other psychopharmacological medication 10 (6.25%) 6 (6.19%) 4 (6.35%) 0.967 −0.003
Statistical analysis: Data are expressed as mean ± standard deviation or absolute number with percentage in parentheses. Differences between two groups were
assessed using the chi-square test. Significant differences are displayed in bold. Phi-coefficient (ϕ) or Cramér’s V (Level of Education) are indicated as markers for the
effect size. BMI, body mass index; DPP-4, dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI,
selective serotonin reuptake inhibitor.
for one man, whereas, EDI-2 data was lacking in one woman.
Regarding ELISA analyses, one outlier for neurotensin and two
outliers for xenin (all in women) were excluded from further
statistical calculations. In the whole study population, the mean
plasma neurotensin concentration was 0.8 ± 0.5 ng/ml (range:
0.1–3.6 ng/ml), mean plasma xenin was 0.9 ± 0.5 ng/ml (range:
0.3–2.9 ng/ml).
Psychometric parameters showed significant differences
between gender groups (Table 1). Women displayed higher
values for all psychometric parameters, namely perceived
stress (+24%), anxiety (+37%), depressiveness (+32%),
and eating disorder symptoms (+27%). Female and male
participants did not show statistical differences concerning
socioeconomic characteristics (Table 2). As shown in
Table 2, female obese patients more often suffered from
binge-eating disorder (BED) than male patients, while
men showed significantly more somatic comorbidities.
Insulin was a significantly more frequent component
of medication in men (Table 2). However, testing these
comorbidities and medication as potential confounders
with help of multivariable linear regression indicated no
significant influence, neither on neurotensin nor on xenin
(Supplementary Table 1).
Patients with diabetes mellitus type 2 did not show differences
in concentrations of neurotensin and xenin compared to those
without diabetes (t-test; data not shown). Likewise, the peptide
levels were similar in patients taking antidiabetic medication like
insulin, DPP-4 antagonists/GLP-1 analogs or other antidiabetics,
and in those without (t-test; data not shown).
After we excluded three women with polycystic ovary
syndrome (PCOS), no significant difference of xenin
concentrations was detectable (p = 0.900; d = 0.018).
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Furthermore, there was no significant difference in
plasma peptide levels between patients taking proton pump
inhibitors (PPIs) or non-steroidal anti-inflammatory drugs
(NSAIDs) and those not (t-test; data not shown). Fatty
liver disease did not demonstrate a significant impact on
neurotensin and xenin (t-test; data not shown). Also, when
using linear regression for testing, we did not observe a
significant predictive power of PPI’s, NSAID’s or of the
diagnosis fatty liver disease, neither on neurotensin, nor xenin
(Supplementary Table 2).
We also conducted multivariable linear regression analyses
in order to estimate the influence of age and gender on xenin
and neurotensin (xenin: R2cor = 0.002; p = 0.319; neurotensin:
R2cor = −0.012; p = 0.968). Additionally, multivariable linear
regression analyses for age and perceived stress, anxiety,
depressiveness and eating disorder pathology, respectively, in
women and men were calculated (Supplementary Table 1).
Sex-Specific Associations Between
Neurotensin and BMI, Age, and
Psychometric Parameters
In men but not in women, a significant weak negative correlation
was observed between BMI and neurotensin plasma levels
(Table 3). Strong positive correlations were observed between
neurotensin and xenin in women and men (Tables 3, 4).
TABLE 3 | Correlation of neurotensin with anthropometric, psychometric and
endocrine parameters.
Parameter Men (n = 63) Women (n = 97)
r p r p
Age (years) 0.113 0.378 −0.028 0.787
BMI (kg/m2) −0.265 0.036 −0.100 0.334
PSQ-20 total score 0.137 0.289 0.231 0.023
- Worries −0.037 0.777 0.188 0.066
- Tension 0.145 0.262 0.274 0.007
- Joy −0.142 0.271 −0.204 0.046
- Demands 0.208 0.105 0.113 0.273
GAD-7 total score 0.027 0.833 0.265 0.009
PHQ-9 total score 0.052 0.687 0.281 0.006
EDI-2 total score −0.200 0.115 0.276 0.007
- Drive for thinness −0.180 0.157 0.212 0.039
- Bulimia −0.192 0.132 0.172 0.096
- Body dissatisfaction −0.237 0.062 0.039 0.706
- Ineffectiveness −0.065 0.613 0.229 0.026
- Perfectionism 0.046 0.719 0.336 0.001
- Interpersonal distrust −0.117 0.360 0.201 0.051
- Interoceptive awareness −0.064 0.620 0.252 0.014
- Maturity fears −0.149 0.244 0.027 0.796
Xenin (ng/ml) 0.731 <0.001 0.788 <0.001
Correlations were assessed using Pearson’s analysis. Significant correlations are
indicated in bold. BMI, body mass index; EDI-2, Eating Disorder Inventory-2; GAD-
7, Generalized Anxiety Disorder-7; PHQ-9, Patient Health Questionnaire-9; PSQ-
20, Perceived Stress Questionnaire-20.
TABLE 4 | Correlation of xenin with anthropometric, psychometric and
endocrine parameters.
Parameter Men (n = 63) Women (n = 97)
r p r p
Age (years) 0.115 0.368 −0.041 0.696
BMI (kg/m2) −0.089 0.487 0.045 0.664
PSQ-20 total score −0.040 0.760 0.254 0.013
- Worries −0.146 0.257 0.205 0.046
- Tension 0.020 0.878 0.267 0.009
- Joy 0.042 0.745 −0.230 0.025
- Demands 0.031 0.812 0.158 0.127
GAD-7 total score −0.088 0.495 0.257 0.012
PHQ-9 total score −0.092 0.472 0.241 0.019
EDI-2 total score −0.152 0.233 0.260 0.011
- Drive for thinness 0.021 0.868 0.274 0.008
- Bulimia −0.142 0.265 0.096 0.359
- Body dissatisfaction −0.168 0.189 0.177 0.088
- Ineffectiveness −0.138 0.282 0.242 0.019
- Perfectionism 0.158 0.215 0.407 <0.001
-Interpersonal distrust −0.169 0.185 0.140 0.178
- Interoceptive awareness −0.133 0.298 0.167 0.107
- Maturity fears −0.108 0.398 −0.076 0.468
Neurotensin (ng/ml) 0.731 <0.001 0.788 <0.001
Correlations were assessed using Pearson’s analysis. Significant correlations are
indicated in bold. BMI, body mass index; EDI-2, Eating Disorder Inventory-2; GAD-
7, Generalized Anxiety Disorder-7; PHQ-9, Patient Health Questionnaire-9; PSQ-
20, Perceived Stress Questionnaire-20.
In women, weak positive correlations between neurotensin
and the total scores of the PSQ-20 (Figure 1), GAD-7 (Figure 2),
PHQ-9 (Figure 3), and EDI-2 (Figure 4) were observed, while
no such associations were observed in men (Table 3). However,
reflecting weak positive correlations (Table 3), no significant
association in multivariable linear regression for the independent
variables of psychometrics (PSQ-20 total score; GAD-7; PHQ-9
and EDI-2 total score) and neurotensin was detectable in women
(R2cor = 0.052; p = 0.066).
Sex-Specific Associations Between
Xenin and BMI, Age, and Psychometrics
Weak positive associations of xenin and the total scores of all
psychometric questionnaires were shown in obese women: PSQ-
20 (Figure 1), GAD-7 (Figure 2), PHQ-9 (Figure 3), and EDI-2
(Figure 4 and Table 4). Due to the weakness of correlations
(Table 4), no significant association in multivariable linear
regression between the independent variables of psychometrics
(PSQ-20 total score; GAD-7; PHQ-9 and EDI-2 total score) and
xenin was detectable in women (R2cor = 0.036; p = 0.123). In men,
no significant correlations of the total and sub scores of applied
psychometrics with xenin were detected (Table 4).
DISCUSSION
The aim of the present study was to examine potential
associations between neurotensin and xenin in plasma
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FIGURE 1 | Correlations between neurotensin and xenin with PSQ-20 total scores in men and women. Overall, in women neurotensin (B) and xenin (D) showed a
positive correlation with PSQ-20 total score. However, for men no significant correlations with PSQ-20 total score were detected, neither for neurotensin (A) nor for
xenin (C). Correlations were calculated using Pearson’s analysis. PSQ-20, Perceived Stress Questionnaire-20.
with psychometrically assessed perceived stress, anxiety,
depressiveness and eating disorder symptoms in patients
with obesity. Positive correlations of neurotensin and xenin
with the above-mentioned psychometric scores were only
detectable in obese women, whereas, no correlations were
observed in obese men.
Mood and anxiety disorders are more prevalent in obese
compared to normal weight subjects (Baumeister and Härter,
2007; Herpertz, 2015). A current study (n = 2,955) demonstrated
increased adjusted odds ratios (OR) for obese participants of the
German National Health Interview and Examination Survey –
Mental Health Supplement at a twelve-months follow up for
mood and anxiety disorders (Jacobi et al., 2004; Baumeister
and Härter, 2007). Especially obese women suffer more often
than obese men from mental comorbidities like anxiety and
mood disorders and pathologic eating behavior (Gater et al.,
1998; Preiss et al., 2013; McHenry et al., 2014; Herpertz, 2015;
Tronieri et al., 2017). This observation is in line with our
current data showing higher values of determined psychological
characteristics in women.
Detected sex-differences might be additionally influenced by
variations in obesity-related stigmatization between women and
men. The stigmatization appears in all facets of everyday life,
verbal and non-verbal, with direct consequences regarding for
example eating habits (Faith et al., 2002; Schwartz et al., 2003;
Puhl and Brownell, 2006). In previous literature, differences
regarding stigmatization exist between obese women and men,
whereby women feel more often affected (Puhl et al., 2008).
Especially middle-aged and morbidly obese females report
great psychological distress (Puhl et al., 2008). This current
stage of research is in line with our finding of higher
psychometric values in obese females. Moreover, the risk for
the development of BED seems to be associated with a high
level of perceived weight-related stigmatization (Almeida et al.,
2011), which is reflected by our result of significantly more
BED diagnoses among women. Potential influencing factors in
this context could be the increased emotional awareness in
addition to the cognitive skill of women to interpret facial
expressions of emotions better than men, as shown in several
studies (Hall and Matsumoto, 2004; Mankus et al., 2016).
Higher values of our female obese patients in the EDI-2
subscale “interoceptive awareness” is a supportive indicator
for this influence.
Studies on various animal models showed decreased
central concentrations of neurotensin under conditions
of obesity (Williams et al., 1991b; Beck et al., 1992). In
the periphery, controversial data have been obtained:
decreased peripheral concentrations of neurotensin were
detected in morbidly obese patients (Weiss et al., 2001),
while another study described a higher risk for high fat
diet-induced obesity in mice with higher concentrations of
peripheral pro-neurotensin (Li et al., 2016) possibly reflecting
species differences. Decreased concentrations of xenin in
plasma of obese children were observed, whereas, obese
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FIGURE 2 | Correlations between neurotensin and xenin with GAD-7 total scores in men and women. Overall, in women neurotensin (B) and xenin (D) showed a
positive correlation with GAD-7 total score, while for men no significant correlations with GAD-7 total score were detected, neither for neurotensin (A) nor for xenin
(C). Correlations were calculated using Pearson’s analysis. GAD-7, Generalized Anxiety Disorder-7.
adolescents showed increased serum levels (Mrozek et al.,
2012; Arslan et al., 2014) pointing toward confounding
factors such as comorbid psychiatric diseases influencing
this association.
In the current study a negative association between
neurotensin and BMI of obese men has been detected,
which is in line with a previous study (Weiss et al., 2001),
whereas, in other studies no difference in neurotensin levels
between obese and lean subjects has been detected (Service
et al., 1986; Auguet et al., 2018). However, these previous
examinations bear several methodical limitations (small sample
size) (Service et al., 1986), and methodical differences (gender
distribution) (Weiss et al., 2001; Auguet et al., 2018). Thus,
the comparability between results of these studies is limited.
We assumed a positive association between psychometric
parameters and BMI because of an increased number of
comorbidities and elevated psychological strain with higher
BMI. Consequently, the negative correlation might conceal
higher plasma levels of neurotensin related to higher scores of
questionnaires in morbidly obese men. However, one has to
note that only an obese spectrum of body weight was assessed in
the present study.
In light of the receptor distribution of NTS1 in certain
brain areas, a role of neurotensin and xenin in the regulation
of stress and emotions can be assumed since NTS1 is highly
expressed in the amygdala and limbic system (Alexander and
Leeman, 1998; Fassio et al., 2000). Regarding neurotensin, both
anxiogenic and anxiolytic effects have been demonstrated in rats
after injection into the bed nucleus of stria terminalis (BNST;
anxiogenic) or ventral pallidum (anxiolytic) (Ollmann et al.,
2015; Normandeau et al., 2018; Li et al., 2020) indicating a
site-dependent effect of the peptide. Mean concentrations of
neurotensin and xenin did not differ between female and male
obese patients in our study, while only women showed positive
correlations of both peptides with the examined psychological
parameters giving rise to a sex-dependent association. A sex-
specific regulation of neurotensin has been suggested previously.
The peptide hormone is considerably higher concentrated
in the anteroventral periventricular nucleus in female rats,
influences the release of gonadotropin-releasing-hormone and
in turn is itself affected by menstrual cycle and estrogens
(Alexander et al., 1991; Herbison and Theodosis, 1991,
1992; Alexander, 1993; Dungan Lemko et al., 2010). As a
consequence, also dysregulated levels of reproductive hormones
in morbidly obese men may have an influence on central
neurotensin concentrations and furthermore on the sex-
dependent associations with psychometrics (Hammoud et al.,
2008). Xenin is less investigated regarding potential sex-
dependent differences compared to neurotensin. A case-control
study showed an increase of serum xenin in women with
PCOS versus women without PCOS (Norman et al., 2007;
Azziz et al., 2016; Guclu et al., 2019). However, co-morbid
PCOS of our female obese inpatients (three women) did
not contribute to divergences of the examined associations.
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FIGURE 3 | Correlations between neurotensin and xenin with PHQ-9 total scores in men and women. Overall, in women neurotensin (B) and xenin (D) showed a
positive correlation with PHQ-9 total score. However, for men no significant correlations with PHQ-9 total score were detected, neither for neurotensin (A) nor for
xenin (C). Correlations were calculated using Pearson’s analysis. PHQ-9, Patient Health Questionnaire-9.
FIGURE 4 | Correlations between neurotensin and xenin with EDI-2 total scores in men and women. Overall, in women neurotensin (B) and xenin (D) showed a
positive correlation with EDI-2 total score, while for men no significant correlations with EDI-2 total score were detected, neither for neurotensin (A) nor for xenin (C).
Correlations were calculated using Pearson’s analysis. EDI-2, Eating Disorder Inventory-2.
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Therefore, sex hormones should be additionally analyzed in
future research.
Neurotensin and stress have been closely linked. Early on
it was shown that icv injection of neurotensin stimulates
the secretion of adrenocorticotropic hormone (ACTH) and
subsequently the adrenal glands in rodents (Gudelsky et al.,
1989). Recently, it was shown that chronic stress induces central
neurotensin release in rats (Normandeau et al., 2018). Orexigenic
signaling through increased HPA axis hormones is a further
stimulus for obesity (Strack et al., 1995; Chrousos, 2009) and
might counteract the anorexigenic effect of neurotensin in CNS.
This may indicate that higher neurotensin levels contribute
to the development and/or maintenance of perceived stress
and anxiety. For xenin, we found positive correlations with
perceived stress and anxiety in women with obesity. In a previous
study, a linear correlation between peripherally measured and
centrally xenin levels gave rise to a transport across the
blood-brain barrier (BBB) (van de Sande-Lee et al., 2013).
Accordingly, given the current controversial state of research,
elevated xenin levels in the CNS of obese women together with
agonistic effects of the peptide at NTS1 may be an indicator
for anxiogenic and stress-inducing consequences (Steele et al.,
2017; Normandeau et al., 2018; Li et al., 2020). However,
clarification of the signaling pathways is necessary to obtain a
more detailed picture.
In the current study, depressiveness was positively correlated
with neurotensin and xenin in obese women only. In this context,
it is to note that female obese patients more often show a
comorbid major depression compared to men (Herpertz, 2015).
Moreover, several items of the PHQ-9, such as “dysregulated
appetite” and “low self-esteem,” overlap with facets of other
psychometric questionnaires (e.g., EDI-2) (Garner, 1991; Thiel
et al., 1997; Löwe et al., 2002). This might suggest that correlations
refer at least partially to similar constructs. In addition, mood
disorders are common comorbidities of eating disorders, in
adolescence and also over the whole lifespan (Casper, 1998;
Swanson et al., 2011). A recent study reported a potential
association between plasma neurotensin and the number of
lifetime suicide attempts in depressive patients, with the result of
a strong positive correlation (Kim et al., 2019) further suggesting
an involvement of neurotensin in the pathogenesis of depression.
Similarly, neurotensin and xenin were correlated with
parameters of disordered eating in obese women only. This
might be related to higher prevalence rates of eating disorders
in women, especially for anorexia nervosa (AN) and for
bulimia nervosa (BN), with up to tenfold higher prevalence in
women (Arbeitsgemeinschaft Wissenschaftlicher Medizinischer
Fachgesellschaften, 2018). BED was more prevalent in our
female participants, which might be contributing to the
lacking correlation in men. Furthermore, an association of sex
hormones with disordered eating behavior and obesity is notable
(Hirschberg, 2012). Testosterone levels are elevated in obese
women following increased chronic stress and hyperinsulinemia,
which promotes binge eating and abdominal fat distribution
(Torres and Nowson, 2007; Hirschberg, 2009, 2012). Moreover,
the HPA axis is overstimulated through endocrine activity of the
abdominal fat (Torres and Nowson, 2007; Pasquali et al., 2008;
Hirschberg, 2009, 2012). In obese men, estradiol concentrations
are elevated and the quantity of abdominal fat leads to lower
testosterone concentrations (Hammoud et al., 2008; Pasquali
et al., 2008; Hirschberg, 2012). Data concerning the relationship
of xenin with depressiveness or disordered eating behavior
are lacking, but due to same receptor and the high sequence
homology, similar explanations as for neurotensin may be
assumed (Feurle, 1998; Maes et al., 2001; Kim and Mizuno, 2010b;
Li et al., 2020). Thus, future studies should focus on xenin.
Several limitations of the study should be kept in mind.
First, we did not assess the menstrual status, and the intake
of estrogen-containing medication was not considered as an
exclusion criterion. Second, due to the naturalistic design
no healthy control group was employed in our study. We
therefore were not able to compare our findings in obese
subjects with normal weight individuals without mental
disorders under study conditions. However, the naturalistic
design is also a strength of this examination because it
reproduces real world conditions during psychosomatic
inpatient treatment. Third, the cross-sectional study design
observes associations, no cause-effect relationships. Hence,
besides experimental studies featuring healthy control
groups, future longitudinal studies are required assessing
neurotensin and xenin levels in the course of psychopathology-
improving therapies. Lastly, heterogeneous comorbidities are
potentially representing confounding factors and therefore
might contribute – besides the relatively small sample
size – to the observed weak associations. Thus, further
studies with bigger sample size or with more stratified study
collectives are needed.
Based on previous literature, increased xenin levels
following treatment with PPI’s as well as decreased plasma
concentrations of neurotensin in women with fatty liver disease
and obesity were described (Stoschus et al., 1998; Auguet
et al., 2018). Previous studies indicated that gastrointestinal
(initiation of gut motility and inhibition of gastric acid
production) and central effects of neurotensin depend on
prostaglandin (Mason et al., 1982; Katsoulis and Conlon,
1988), why we investigated a possible influence of the intake of
NSAID’s on peptide levels. Until know, interactions between
NSAID’s and xenin were not assessed, but imaginable
(Stoschus et al., 1998; Kapraali et al., 1999). However,
in our study NSAID’s did not affect peripheral levels of
neurotensin or xenin.
Taken together, we observed positive correlations of
neurotensin and xenin with stress, anxiety, depressiveness
and eating disorder symptoms in obese women, whereas,
associations were absent in male patients with obesity indicating
a sex-specific association. Whether this association represents
a causal relationship should be further investigated. If so,
it would be interesting to investigate whether inhibition
of these peptides could exert a beneficial effect on these
psychometric parameters. Lastly, due to the sequence
homology between neurotensin and xenin along with the –
at least in part – similar activation of the NTS1 it will be
interesting to investigate whether the peptides are be able to
compensate each other.
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